Trial Summary
What is the purpose of this trial?In this research study the investigators are looking at a type of radiation called proton radiation. Proton radiation has been shown to deliver virtually no radiation beyond the area of the tumor, sparing surrounding normal tissue from exposure. This may reduce side effects that patients would normally experience with conventional radiation therapy.
In this research study the investigators are looking to determine if proton radiation with a reduced field size will be as effective in controlling tumor growth as photon therapy, while reducing the treatment-related side effects observed in patients with brain tumors.
Eligibility Criteria
This trial is for people with specific brain tumors called low-grade gliomas or Grade III anaplastic glioma, which have certain genetic features. Participants must need radiation therapy, be expected to live more than 5 years, speak English, and be able to undergo MRI scans and cognitive tests.Inclusion Criteria
I need to undergo radiation therapy.
Life expectancy greater than 5 years
Willing to participate in rigorous neurocognitive evaluations at baseline and serially following treatment
+4 more
Exclusion Criteria
Baseline neurocognitive or emotional disorders
Pregnant or breastfeeding
I have been cancer-free from a different cancer for over 5 years.
+5 more
Participant Groups
The study is testing proton radiation therapy to see if it can control tumor growth as effectively as photon therapy while reducing side effects. Proton radiation aims to spare healthy tissue from exposure unlike conventional therapies.
1Treatment groups
Experimental Treatment
Group I: Proton radiation therapyExperimental Treatment1 Intervention
Single arm study delivering fractionated proton therapy over 6 week (54-59.4 Gy(RBE))
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Massachusetts General HospitalBoston, MA
Loading ...
Who Is Running the Clinical Trial?
Massachusetts General HospitalLead Sponsor
National Cancer Institute (NCI)Collaborator